The stock of RAPT Therapeutics Inc (RAPT) has seen a -15.03% decrease in the past week, with a 18.38% gain in the past month, and a -25.94% decrease in the past quarter. The volatility ratio for the week is 11.93%, and the volatility levels for the past 30 days are at 13.82% for RAPT. The simple moving average for the past 20 days is 3.25% for RAPT’s stock, with a -58.21% simple moving average for the past 200 days.
Is It Worth Investing in RAPT Therapeutics Inc (NASDAQ: RAPT) Right Now?
Additionally, the 36-month beta value for RAPT is 0.06. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 4 rating it as “hold,” and 0 rating it as “sell.”
The public float for RAPT is 34.96M and currently, short sellers hold a 4.91% ratio of that float. The average trading volume of RAPT on January 10, 2025 was 3.22M shares.
RAPT) stock’s latest price update
RAPT Therapeutics Inc (NASDAQ: RAPT) has experienced a decline in its stock price by -4.48 compared to its previous closing price of 1.45. However, the company has seen a fall of -15.03% in its stock price over the last five trading days. globenewswire.com reported 2025-01-09 that SOUTH SAN FRANCISCO, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 9:00 a.m. Pacific Time.
Analysts’ Opinion of RAPT
Many brokerage firms have already submitted their reports for RAPT stocks, with H.C. Wainwright repeating the rating for RAPT by listing it as a “Buy.” The predicted price for RAPT in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on December 26, 2024 of the previous year 2024.
Stifel, on the other hand, stated in their research note that they expect to see RAPT reach a price target of $2, previously predicting the price at $7. The rating they have provided for RAPT stocks is “Hold” according to the report published on November 13th, 2024.
Piper Sandler gave a rating of “Neutral” to RAPT, setting the target price at $2 in the report published on November 11th of the previous year.
RAPT Trading at -6.56% from the 50-Day Moving Average
After a stumble in the market that brought RAPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.94% of loss for the given period.
Volatility was left at 13.82%, however, over the last 30 days, the volatility rate increased by 11.93%, as shares surge +28.90% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -27.20% lower at present.
During the last 5 trading sessions, RAPT fell by -13.80%, which changed the moving average for the period of 200-days by -83.01% in comparison to the 20-day moving average, which settled at $1.3425. In addition, RAPT Therapeutics Inc saw -12.34% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for RAPT
Current profitability levels for the company are sitting at:
- -21.72 for the present operating margin
- 0.82 for the gross margin
The net margin for RAPT Therapeutics Inc stands at -20.33. The total capital return value is set at -1.17. Equity return is now at value -80.13, with -69.76 for asset returns.
Currently, EBITDA for the company is -125.85 million with net debt to EBITDA at 0.29. When we switch over and look at the enterprise to sales, we see a ratio of 3.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.90.
Conclusion
In conclusion, RAPT Therapeutics Inc (RAPT) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
